European Hospital Anticoagulant Market Dominated by Sanofi-Aventis's Clexane
New Hospital Anticoagulant Audit Now Available From Arlington Medical Resources
MALVERN, Pa., Sept. 28 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that more than half of all European inpatients who receive anticoagulants during their hospital stay are administered Sanofi-Aventis's Clexane (marketed as Lovenox in the U.S. and France).
The new audit entitled The European Hospital Anticoagulant Market Guide is a comprehensive source for anticoagulant use in European hospitals. Released quarterly, the audit contains detailed clinical data from thousands of hospitalized patients receiving anticoagulants. Survey results are projected to the national level for France, Germany, Italy, Spain and the United Kingdom.
The audit also reveals that surgical venous thromboembolism (VTE) primary prophylaxis accounts for the largest share of inpatient anticoagulant use at 48 percent of all inpatients. However, non-surgical VTE and stroke prophylaxis remains a key area of growth opportunity for companies marketing and developing anticoagulant agents.
The European Hospital Anticoagulant Market Guide is designed to help biopharmaceutical companies quantify targeted patient segments, better understand treatment practices and customers, size commercial opportunity and formulate clinical development strategy.
Besides Clexane, Boehringer Ingelheim's Pradaxa, Bayer's Xarelto and all other anticoagulants used in European hospitals are tracked in this audit.
About AMR
AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
SOURCE Arlington Medical Resources
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article